1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Drugs In Development, 2022, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 29, 225, 260, 11, 31, 226, 51 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 10, 12, 2, 1, 12 and 3 molecules, respectively.
Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Gastric Cancer - Overview
- Gastric Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Gastric Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Gastric Cancer - Companies Involved in Therapeutics Development
- Gastric Cancer - Drug Profiles
- Gastric Cancer - Dormant Projects
- Gastric Cancer - Discontinued Products
- Gastric Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Gastric Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products under Development by Universities/Institutes, 2022 (Contd..1)
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Products under Development by Universities/Institutes, 2022 (Contd..1)
- Products under Development by Universities/Institutes, 2022 (Contd..2)
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Gastric Cancer - Dormant Projects, 2022
- Gastric Cancer - Dormant Projects, 2022 (Contd..1)
- Gastric Cancer - Discontinued Products, 2022
- Number of Products under Development for Gastric Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- A28 Therapeutics Inc
- Abbisko Cayman Limited
- AbbVie Inc
- Abclon Inc
- Abion Inc
- ABL Bio Inc
- Abpro Corp
- AbTis Co Ltd
- Accurus Biosciences Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- Affimed GmbH
- AffyImmune Therapeutics Inc
- Agenus Inc
- AIMM Therapeutics BV
- Akeso Inc
- Alkermes Plc
- Alligator Bioscience AB
- Alphamab Oncology
- Alteogen Inc
- AltruBio Inc
- ALX Oncology Holdings Inc
- Ambrx Biopharma Inc
- amcure GmbH
- Amgen Inc
- Aminex Therapeutics Inc
- Amunix Operating Inc
- Andes Biotechnologies
- Anhui Anke Biotechnology (Group) Co Ltd
- Antengene Corp Ltd
- Antikor Biopharma Ltd
- Apollomics Inc
- Apotex Inc
- Aprea Therapeutics Inc
- Aptacure Therapeutics Ltd
- Arbele Ltd
- Arcus Biosciences Inc
- Argonaut Therapeutics Ltd
- Arromax Pharmatech Co Ltd
- Aryogen Pharmed Co
- Asana BioSciences LLC
- Ascelia Pharma AB
- Ascenta Therapeutics Inc
- Ascentage Pharma Group Inc
- Ascentage Pharma Group International
- Ascentawits Pharmaceuticals Ltd
- AskAt Inc
- AskGene Pharma Inc
- Aslan Pharmaceuticals Ltd
- Astellas Pharma Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Aurora BioPharma Inc
- Avvinity Therapeutics Ltd
- Basilea Pharmaceutica Ltd
- Bavarian Nordic AS
- Bayer AG
- BeiGene Ltd
- Beijing BGI-GBI Biotech Co Ltd
- Beijing Biostar Technologies Ltd
- Beijing Hanmi Pharmaceutical Co Ltd
- Beijing Immunochina Pharmaceuticals Co Ltd
- Beijing Jingda Biotechnology Co Ltd
- Beijing Konruns Pharmaceutical Co Ltd
- Beijing Mabworks Biotech Co Ltd
- Beijing Scitech-MQ Pharmaceuticals Ltd
- Beijing Syngentech Co Ltd
- Beijing Wuhe Boao Pharmaceutical Technology Development Co Ltd
- Beijng Immunoah Pharma Tech Co Ltd
- Bellicum Pharmaceuticals Inc
- Betta Pharmaceuticals Co Ltd
- Bicara Therapeutics Inc
- Bicycle Therapeutics Plc
- Bika Biotechnology Guanzhou Co Ltd
- Bio-Synectics Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- BioEclipse Therapeutics Inc
- BioIntegrator
- BioInvent International AB
- BioLineRx Ltd
- BioMed Valley Discoveries Inc
- Biomunex Pharmaceuticals
- BioNTech SE
- Biosion Inc
- Biosplice Therapeutics Inc
- BioSyngen Pte Ltd
- Biotecnol Ltd
- Biotheus Inc
- Bioviz Technologies Pvt Ltd
- BJ Bioscience Inc
- Bliss Biopharmaceutical (Hangzhou) Co Ltd
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Bolt Biotherapeutics Inc
- BreakBio Corp
- BrickBio Inc
- BridgeBio Pharma Inc
- BrightGene Bio-Medical Technology Co Ltd
- Bristol-Myers Squibb Co
- Byondis BV
- Calithera Biosciences Inc
- CalyGene Biotechnology Inc
- CanBas Co Ltd
- Carisma Therapeutics Inc
- Carrier (Beijing) Pharmaceutical Co Ltd
- CARsgen Therapeutics Ltd
- CAS-Lamvac Biotech Co Ltd
- Catalent Inc
- Catamaran Bio Inc
- Cedilla Therapeutics
- Celldex Therapeutics Inc
- Cellestia Biotech AG
- Cellid Co Ltd
- Cellivery Therapeutics Inc
- Cellix Bio Pvt Ltd
- Cello Therapeutics Inc
- Celon Pharma SA
- Celularity Inc
- Cend Therapeutics Inc
- Centrymed Pharmaceutical Inc
- CGeneTech (Suzhou China) Co Ltd
- Cheetah Cell Therapeutics Co Ltd
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimeric Therapeutics Ltd
- China Immunotech (Beijing) Biotechnology Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Chongqing Precision Biotech Co Ltd
- Chugai Pharmaceutical Co Ltd
- Cloaked Therapeutics LLC
- CMG Pharmaceutical Co Ltd
- CNBX Pharmaceuticals Inc
- Codiak BioSciences Inc
- Coherent Biopharma
- Conagen Inc
- Convalife
- CSPC Pharmaceutical Group Ltd
- CStone Pharmaceuticals Co Ltd
- CTG Pharma Ltd
- Cue Biopharma Inc
- Cumberland Pharmaceuticals Inc
- Curegenix Inc
- CureLab Oncology Inc
- CureMeta LLC
- Cytodyn Inc
- CytoImmune Therapeutics Inc
- CytomX Therapeutics Inc
- D3 Bio Inc
- Daiichi Sankyo Co Ltd
- Defence Therapeutics Inc
- Delta-Fly Pharma Inc
- Diaccurate
- DiNonA Inc
- DM Bio Ltd
- DNAtrix Inc
- Dongguan Daxin Biotechnology Co Ltd
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- Duo Oncology Inc
- Dyadic International Inc
- DynamiCure Biotechnology LLC
- Eddingpharm Inc
- Eden Biologics Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ella Therapeutics Ltd
- Ellipses Pharma Ltd
- Elpiscience Biopharma Ltd
- Elucida Oncology Inc
- EOS Biosciences Inc
- EpimAb Biotherapeutics Inc
- EpiThany Inc
- Epsilogen Ltd
- ERYTECH Pharma SA
- Etern BioPharma Co Ltd
- eTheRNA Immunotherapies NV
- Eutilex Co Ltd
- Evopoint Bioscience Co Ltd
- Excelmab Inc
- Exeliom Biosciences SAS
- Exelixis Inc
- EXUMA Biotech Inc
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- f5 Therapeutics Inc
- Faron Pharmaceuticals Oy
- Fate Therapeutics Inc
- Frost Biologic Inc
- Fusion Pharmaceuticals Inc
- FutureGen Biopharm Technology Co Ltd
- G+FLAS Life Sciences Inc
- GAiA BioMedicine Inc
- Galecto Inc
- GC Biopharma Corp
- Geneius Biotechnology Inc
- Genentech USA Inc
- GeneQuantum Healthcare Suzhou Co Ltd
- GeneScience Pharmaceuticals Co Ltd
- Genexine Inc
- GenoImmune Therapeutics Biotechnology Co Ltd
- Genome & Co
- Genor BioPharma Co Ltd
- GI Innovation Co Ltd
- Gilead Sciences Inc
- GLG Pharma SA
- GlycoNex Inc
- Glycotope GmbH
- GO Therapeutics Inc
- Good T Cells Inc
- Green Cross LabCell Corp
- Grid Therapeutics LLC
- GSK plc
- GT Biopharma Inc
- Guangdong Yinzhu Pharmaceutical Technology Co Ltd
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Doublle Bioproduct Inc
- Guangzhou Yinming Biomedical Technology Co Ltd
- Haikou Qili Pharmaceutical Co Ltd
- HaimBio Ltd
- Hangzhou Bensheng Pharmaceutical Co Ltd
- Hangzhou DAC Biotech Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- HebeCell Corp
- Hebei Senlang Biotechnology Co Ltd
- Helixmith Co Ltd
- Hibercell Inc
- HiFiBiO Therapeutics Inc
- Highlight Therapeutics SL
- Hillstream BioPharma Inc
- HitGen Inc
- Horizon Therapeutics Plc
- Huabo Biopharm (Shanghai) Co Ltd
- Huadao Shanghai Biomedical Co Ltd
- Huahui Anjian (Beijing) Biotechnology Co Ltd
- Hummingbird Bioscience Pte Ltd
- Hutchison MediPharma Ltd
- I-Mab
- Ideaya Biosciences Inc
- Idience Co Ltd
- IGM Biosciences Inc
- ImCheck Therapeutics SAS
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunisbio Co Ltd
- ImmunityBio Inc
- Immunocore Holdings Plc
- Immunocore Limited
- Immunomet Therapeutics Inc
- Immunomic Therapeutics Inc
- Immunotech Biopharm Ltd
- ImmVirX Pty Ltd
- Imugene Ltd
- Incyte Corp
- Inhibrx Inc
- Innate Pharma SA
- Inner Mongolia Qite Biotechnology (Group) Co Ltd
- Innovative Cellular Therapeutics Co Ltd
- Innovent Biologics Inc
- Inovio Pharmaceuticals Inc
- Intocell Inc
- Intra-Immusg Pvt Ltd
- InxMed (Beijing) Co Ltd
- Ipsen SA
- Istari Oncology Inc
- Ithax Pharmaceuticals Inc
- JenKem Technology Co Ltd
- Jiangsu Aosaikang Pharmaceutical Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- Jina Pharmaceuticals Inc
- Jiuzhitang Co Ltd
- Johnson & Johnson
- Joint Biosciences Ltd
- Jounce Therapeutics Inc
- JW Pharmaceutical Corp
- Karyo Biologics LLC
- Karyopharm Therapeutics Inc
- KeyMed Biosciences Inc
- Keythera Pharmaceuticals Co Ltd
- Kintor Pharmaceutical Ltd
- Kirilys Therapeutics Inc
- KLUS Pharma Inc
- Komipharm International Co Ltd
- Kringle Pharma Inc
- Kronos Bio Inc
- Kupffer Biotherapeutics Inc
- Kymab Ltd
- Kyowa Kirin Co Ltd
- L&L Biopharma Co Ltd
- Laekna Therapeutics Shanghai Co Ltd
- LaNova Medicines Ltd
- LATITUDE Pharmaceuticals Inc
- Lead Discovery Center GmbH
- Leap Therapeutics Inc
- Legend Biotech Corp
- LegoChem Biosciences Inc
- Lepu Biopharma Co Ltd
- Les Laboratoires Servier SAS
- Leukocare AG
- Liangjiang Medicine Co Ltd
- Liminatus Pharma LLC
- Lindis Biotech GmbH
- LintonPharm Co Ltd
- Lion TCR Pte Ltd
- LipoMedix Pharmaceutical Inc
- Livzon Pharmaceutical Group Co Ltd
- Luye Pharma Group Ltd
- Lycera Corp
- Lyvgen Biopharma Ltd
- Mabpharm Ltd
- MacroGenics Inc
- Maxinovel Pharmaceuticals
- MaxiVAX SA
- MBQ Pharma Inc
- Mecox Cure Med Co Ltd
- MedAbome Inc
- Medicenna Therapeutics Corp
- Meditope Biosciences Inc
- MedPacto Inc
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Mersana Therapeutics Inc
- Merus NV
- Metagone Biotech Inc
- Metis Precision Medicine
- Midissia Therapeutics Inc
- Mirati Therapeutics Inc
- Mitsubishi Tanabe Pharma Corp
- Molecular Partners AG
- Molecular Templates Inc
- Moleculin Biotech Inc
- Morphogenesis Inc
- MorphoSys AG
- Multitude therapeutics Inc
- Mustang Bio Inc
- Mycenax Biotech Inc
- Myeloid Therapeutics Inc
- Nanjing Bioheng Biotech Co Ltd
- Nanjing CART Medical Technology Co Ltd
- Nanjing Tianyi Bioscience Co Ltd
- NanoCarrier Co Ltd
- NanoMab Technology Ltd
- NeuClone Pty Ltd
- NewBio Therapeutics Inc
- NextCure Inc
- NGM Biopharmaceuticals Inc
- Nimbus Therapeutics LLC
- Nouscom AG
- NovaRock Biotherapeutics Inc
- Novartis AG
- Nurix Therapeutics Inc
- OBI Pharma Inc
- Ocellaris Pharma Inc
- Ona Therapeutics SL
- OncoC4 Inc
- OncoInsight Co Ltd
- Oncolys BioPharma Inc
- Oncomatryx Biopharma SL
- Onconic Therapeutics Co Ltd
- OncoOne Research & Development GmbH
- OncoSynergy Inc
- OncoTherapy Science Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Onxeo SA
- OPKO Health Inc
- Orano Med LLC
- Origincell Technology Group Co Ltd
- Otsuka Holdings Co Ltd
- Oxford BioTherapeutics Ltd
- Palleon Pharmaceuticals Inc
- Panbela Therapeutics Inc
- Papyrus Therapeutics Inc
- Parasol Biotech Co Ltd
- Patrys Ltd
- Pfizer Inc
- Phanes Therapeutics Inc
- Pharma Mar SA
- Pharmapraxis
- Philogen SpA
- Pieris Pharmaceuticals Inc
- Pionyr Immunotherapeutics Inc
- PlantForm Corp
- Plus Therapeutics Inc
- PMV Pharmaceuticals Inc
- PNB Vesper Life Science Pvt Ltd
- Portage Biotech Inc
- Potenza Therapeutics Inc
- Precirix NV
- Prescient Therapeutics Ltd
- Prestige BioPharma Ltd
- Promontory Therapeutics Inc
- Protheragen Inc
- PsiOxus Therapeutics Ltd
- Puma Biotechnology Inc
- Qilu Pharmaceutical Co Ltd
- Qilu Puget Sound Biotherapeutics Corp
- Quadriga BioSciences Inc
- QureBio Ltd
- Qurient Co Ltd
- Rakuten Medical Inc
- Rapa Therapeutics LLC
- RAPT Therapeutics Inc
- RaQualia Pharma Inc
- Redx Pharma Plc
- Regeneron Pharmaceuticals Inc
- RemeGen Co Ltd
- Replimune Ltd
- Rhizen Pharmaceuticals SA
- Roivant Sciences Inc
- RS Research
- Russian Pharmaceutical Technologies
- S.Biomedics Co Ltd
- Sanofi
- Scancell Holdings Plc
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Seven and Eight Biopharmaceuticals Corp
- Shandong Boan Biotechnology Co Ltd
- Shandong Golden Brick Biotechnology Co Ltd
- Shanghai Bioray Laboratory Inc
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai GeneChem Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Henlius Biotech Inc
- Shanghai icell Biotechnology Co Ltd
- Shanghai Jiabao Yaoyin Pharmaceutical Technology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Longyao Biotechnology Co Ltd
- Shanghai Miracogen Inc
- Shanghai PerHum Therapeutics Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Sunstem Biotechnology Co Ltd
- Shanghai Xunhe Pharmaceutical Technology Co Ltd
- Shanghai Yihao Biotechnology Co Ltd
- Shanghai Yituo Pharmaceutical Technology Co Ltd
- Shanghai Yuyao Biotechnology Ltd
- Shenogen Pharma Group Ltd
- Shenyang Dongxing Pharmaceutical Co Ltd
- Shenzhen BinDeBio Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shenzhen Fapon Biopharma Inc
- Shenzhen NeoCura Biotechnology Corp
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shijiazhuang No. 4 Pharmaceutical Co Ltd
- Shijiazhuang Sagacity New Drug Development Co Ltd
- Shionogi & Co Ltd
- Sichuan Kelun Pharmaceutical Co Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Sillajen Biotherapeutics
- Simcha Therapeutics Inc
- Sino Biopharmaceutical Ltd
- SinoCelltech Group Ltd
- SN BioScience
- Sorrento Therapeutics Inc
- SOTIO Biotech AS
- Sparx Therapeutics Inc
- ST Pharm Co Ltd
- Statera Biopharma Inc
- Stemirna Therapeutics Ltd
- Sumitomo Pharma Co Ltd
- Suntec Medical (Taiwan) Inc
- Surface Oncology Inc
- Suzhou Maximum Bio-tech Co Ltd
- Suzhou Zanrong Pharmaceutical Technology Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Suzhou Zerun New Drug Research and Development Co Ltd
- Symphogen A/S
- SynCore Biotechnology Co Ltd
- SynOx Therapeutics Ltd
- Systimmune Inc
- T-Cure Bioscience Inc
- Tachyon Therapeutics Inc
- TAE Life Sciences LLC
- Taiho Oncology Inc
- Taiho Pharmaceutical Co Ltd
- Takeda Pharmaceutical Co Ltd
- Takis Srl
- TargImmune Therapeutics AG
- Tarveda Therapeutics Inc
- Tasly Pharmaceutical Group Co Ltd
- TCRx Therapeutics Co Ltd
- Teclison Ltd
- Tempest Therapeutics Inc
- Tessa Therapeutics Ltd
- Tonix Pharmaceuticals Holding Corp
- Toray Industries Inc
- TOT Biopharm Co Ltd
- Totus Medicines Inc
- Transcenta Holding Ltd
- TransThera Sciences (Nanjing) Inc
- Treos Bio Ltd
- Trio Medicines Ltd
- Trishula Therapeutics Inc
- Triumvira Immunologics Inc
- Turning Point Therapeutics Inc
- Turnstone Biologics Inc
- Tvardi Therapeutics Inc
- Tyg Oncology Ltd
- UCB SA
- United BioPharma Inc
- United Immunity Co Ltd
- VacV Biotherapeutics Ltd
- Vaxon Biotech
- Vedanta Biosciences Inc
- Venus Remedies Ltd
- Viracta Therapeutics Inc
- VM Discovery Inc
- Wellington Zhaotai Therapies Ltd
- Wuhan YZY Biopharma Co Ltd
- Xcovery Holding Co LLC
- Xencor Inc
- Xiangxue Life Sciences
- XuanZhu Biological Technology Co Ltd
- Zai Lab Ltd
- Zhejiang Borui Biopharmaceutical Co Ltd
- Zhejiang Doer Biologics Corp
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang Jianfeng Group Company Ltd
- Zhejiang Landun Pharmaceutical Co Ltd
- Zhuhai Beihai Biotech Co Ltd
- Zymeworks Inc
